FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P. Angus, Gary L. Johnson, Xiaping He et al.|npj Breast Cancer|2021Cited by 24
Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancerMaki Tanioka, Charles M. Perou, Kevin R. Mott et al.|Genome Medicine|2018Cited by 18
Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.Aranzazu Fernández-Martínez, Charles M. Perou, Maki Tanioka et al.|Journal of Clinical Oncology|2019Cited by 7
Processed TCGA pan-cancer data set used in the I-Boost paper (Wong et al. 2019)Kin Yau Wong, Charles M. Perou, Cheng Fan et al.|Zenodo (CERN European Organization for Nuclear Research)|2019Cited by 1
Genetic causes of resistance to entinostat in luminal breast cancer model systems.Maki Tanioka, Charles M. Perou, Joe Garay et al.|Journal of Clinical Oncology|2017Cited by 0